{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:11:13Z","timestamp":1790892673322,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add\u2010on liraglutide, sitagliptin, or insulin glargine in this 26\u2010week trial. The primary endpoint was the change in intrahepatic lipid (IHL) from baseline to week 26 as quantified by magnetic resonance imaging\u2013estimated proton density fat fraction (MRI\u2010PDFF). Secondary endpoints included changes in abdominal adiposity (subcutaneous adipose tissue [SAT] and visceral adipose tissue [VAT]), glycated hemoglobin, and body weight from baseline to week 26. We analysed data from intent\u2010to\u2010treat population. MRI\u2010PDFF, VAT, and weight decreased significantly with liraglutide (15.4% \u00b1 5.6% to 12.5% \u00b1 6.4%, <jats:italic toggle=\"yes\">P <\/jats:italic>&lt; 0.001; 171.4 \u00b1 27.8 to 150.5 \u00b1 30.8, <jats:italic toggle=\"yes\">P <\/jats:italic>= 0.003; 86.6 \u00b1 12.9 kg to 82.9 \u00b1 11.1 kg, <jats:italic toggle=\"yes\">P <\/jats:italic>= 0.005, respectively) and sitagliptin (15.5% \u00b1 5.6% to 11.7% \u00b1 5.0%, <jats:italic toggle=\"yes\">P <\/jats:italic>= 0.001; 153.4 \u00b1 31.5 to 139.8 \u00b1 27.3, <jats:italic toggle=\"yes\">P <\/jats:italic>= 0.027; 88.2 \u00b1 13.6 kg to 86.5 \u00b1 13.2 kg, <jats:italic toggle=\"yes\">P <\/jats:italic>= 0.005, respectively). No significant change in MRI\u2010PDFF, VAT, or body weight was observed with insulin glargine. SAT decreased significantly in the liraglutide group (239.9 \u00b1 69.0 to 211.3 \u00b1 76.1; <jats:italic toggle=\"yes\">P <\/jats:italic>= 0.020) but not in the sitagliptin and insulin glargine groups. Changes from baseline in MRI\u2010PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> Combined with metformin, both liraglutide and sitagliptin, but not insulin glargine, reduced body weight, IHL, and VAT in addition to improving glycemic control in patients with T2DM and NAFLD.<\/jats:p>","DOI":"10.1002\/hep.30320","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T06:28:30Z","timestamp":1540016910000},"page":"2414-2426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":244,"title":["Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease"],"prefix":"10.1097","volume":"69","author":[{"given":"Jinhua","family":"Yan","sequence":"first","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yao","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Kuang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Harbin Medical University,Harbin,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubin","family":"Yang","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[{"name":"Changhai Hospital,Shanghai,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianpei","family":"Hong","sequence":"additional","affiliation":[{"name":"Peking University Third Hospital,Beijing,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushu","family":"Li","sequence":"additional","affiliation":[{"name":"The First Hospital of China Medical University,Shenyang,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Dou","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital,Beijing,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Yang","sequence":"additional","affiliation":[{"name":"CHINA\u2010JAPAN Friendship Hospital,Beijing,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Qin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Henan Provincial Peoples Hospital,Zhengzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital,Beijing,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"Luo","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyan","family":"Shan","sequence":"additional","affiliation":[{"name":"The First Hospital of China Medical University,Shenyang,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrong","family":"Deng","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Xu","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyi","family":"Zeng","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Kang","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6392-1163","authenticated-orcid":false,"given":"Jianping","family":"Weng","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat\u2010sen University, Guangdong Provincial Key Laboratory of Diabetology,Guangzhou,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"hep30320-bib-0001-20250212","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30320-bib-0002-20250212","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2010EASD\u2010EASO Clinical Practice Guidelines for the management of non\u2010alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"hep30320-bib-0003-20250212","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jhep.2008.10.010","article-title":"Epidemiology of non\u2010alcoholic fatty liver disease in China","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"hep30320-bib-0004-20250212","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2010meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep30320-bib-0005-20250212","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"hep30320-bib-0006-20250212","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","year":"2010","journal-title":"J Hepatol"},{"key":"hep30320-bib-0007-20250212","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non\u2010alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"hep30320-bib-0008-20250212","first-page":"S1","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"hep30320-bib-0009-20250212","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non\u2010alcoholic fatty liver disease: A systematic review and meta\u2010analysis","volume":"1","year":"2013","journal-title":"Biomed Rep"},{"key":"hep30320-bib-0010-20250212","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non\u2010alcoholic fatty liver disease: A randomized controlled trial","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep30320-bib-0011-20250212","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non\u2010alcoholic steatohepatitis (LEAN): A multicentre, double\u2010blind, randomised, placebo\u2010controlled phase 2 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"hep30320-bib-0012-20250212","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: A randomized trial","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"hep30320-bib-0013-20250212","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: A randomised placebo\u2010controlled trial","volume":"59","year":"2016","journal-title":"Diabetologia"},{"key":"hep30320-bib-0014-20250212","first-page":"1054","article-title":"Basal insulin peglispro vs insulin glargine in insulin\u2010na\u0457ve type 2 diabetes: IMAGINE 2 randomized trial","volume":"18","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"hep30320-bib-0015-20250212","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2337\/dc15-1531","article-title":"Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"hep30320-bib-0016-20250212","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/dmrr.2827","article-title":"Chinese Diabetes Society. Standards of care for type 2 diabetes in China","volume":"32","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"hep30320-bib-0017-20250212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0284185115580488","article-title":"A comparison of liver fat content as determined by magnetic resonance imaging\u2010proton density fat fraction and MRS versus liver histology in non\u2010alcoholic fatty liver disease","volume":"57","year":"2016","journal-title":"Acta Radiol"},{"key":"hep30320-bib-0018-20250212","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00330-015-3703-6","article-title":"Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis","volume":"25","year":"2015","journal-title":"Eur Radiol"},{"key":"hep30320-bib-0019-20250212","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Sirlin CB, Loomba R. Non\u2010invasive, quantitative assessment of liver fat by MRI\u2010PDFF as an endpoint in NASH trials","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep30320-bib-0020-20250212","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30320-bib-0021-20250212","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long\u2010term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","year":"2013","journal-title":"Gastroenterology"},{"key":"hep30320-bib-0022-20250212","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00592-014-0638-3","article-title":"Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug\u2010naive subjects with type 2 diabetes","volume":"51","year":"2014","journal-title":"Acta Diabetol"},{"key":"hep30320-bib-0023-20250212","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira\u2010NAFLD Study","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"hep30320-bib-0024-20250212","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non\u2010alcoholic steatohepatitis and non\u2010alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN\u2010J)","volume":"45","year":"2015","journal-title":"Hepatol Res"},{"key":"hep30320-bib-0025-20250212","doi-asserted-by":"crossref","first-page":"e50117","DOI":"10.1371\/journal.pone.0050117","article-title":"Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonists","volume":"7","year":"2012","journal-title":"PLoS ONE"},{"key":"hep30320-bib-0026-20250212","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","article-title":"iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy","volume":"24","year":"2016","journal-title":"Cell Metab"},{"key":"hep30320-bib-0027-20250212","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00125-016-3896-5","article-title":"GLP\u20101 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1","volume":"59","year":"2016","journal-title":"Diabetologia"},{"key":"hep30320-bib-0028-20250212","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dom.12674","article-title":"Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: A 26\u2010week, open\u2010label, randomized, active comparator clinical trial","volume":"18","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"hep30320-bib-0029-20250212","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta\u2010analysis","volume":"60","year":"2011","journal-title":"Metabolism"},{"key":"hep30320-bib-0030-20250212","first-page":"548","article-title":"Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease","volume":"12","year":"2013","journal-title":"Ann Hepatol"},{"key":"hep30320-bib-0031-20250212","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2018.01.035","article-title":"Prolactin improves hepatic steatosis via CD36 pathway","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep30320-bib-0032-20250212","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/hepr.12816","article-title":"Signal transducer and activator of transcription 5 plays a crucial role in hepaticlipid metabolism through regulation of CD36 expression","volume":"47","year":"2017","journal-title":"Hepatol Res"},{"key":"hep30320-bib-0033-20250212","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide effect and action in diabetes 5 (LEAD\u20105) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD\u20105 met+SU): A randomised controlled trial","volume":"52","year":"2009","journal-title":"Diabetologia"},{"key":"hep30320-bib-0034-20250212","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon\u2010like peptide\u20101 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD\u20104 Met+TZD)","volume":"32","year":"2009","journal-title":"Diabetes Care"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201906000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T21:01:41Z","timestamp":1739394101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201906000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30320","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"2018-05-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}